Inicio>>Signaling Pathways>> PROTAC>>Propargyl-PEG2-acid

Propargyl-PEG2-acid

Catalog No.GC61551

Propargyl-PEG2-acid es un conector ADC de PEG de 2 unidades no escindible que se utiliza en la sÍntesis de conjugados de anticuerpo-fÁrmaco (ADC). Propargyl-PEG2-acid también es un conector PROTAC basado en PEG que se puede usar en la sÍntesis de PROTAC.

Products are for research use only. Not for human use. We do not sell to patients.

Propargyl-PEG2-acid Chemical Structure

Cas No.: 1859379-85-3

Tamaño Precio Disponibilidad Cantidad
100 mg
32,00 $
Disponible
250 mg
59,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Propargyl-PEG2-acid is a non-cleavable 2 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Propargyl-PEG2-acid is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs[1].

ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker[1].PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[1].

[1]. Sano K, et al. Short PEG-linkers improve the performance of targeted, activatable monoclonal antibody-indocyanine green optical imaging probes. Bioconjug Chem. 2013 May 15;24(5):811-6.

Reseñas

Review for Propargyl-PEG2-acid

Average Rating: 5 ★★★★★ (Based on Reviews and 2 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Propargyl-PEG2-acid

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.